{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fang Y"],"funding":["High Level Scientific and Technological Talents Project of Lvliang City","National Natural Science Foundation of China","Ningxia Agricultural Science and Technology Independent Innovation Special Project - Scientific and Technological Innovation Guidance Project","Scientific Research Start Funds for Advanced Talent in Ningxia Province"],"pagination":["521"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12374472"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(1)"],"pubmed_abstract":["Toxoplasma gondii (T. gondii) is a globally prevalent zoonotic parasite causing severe health and economic impacts. Despite decades of research, no commercial vaccine provides comprehensive protection against both acute and chronic toxoplasmosis. DNA vaccines represent a promising strategy, but their application is hindered by low delivery efficiency and limited immunogenicity. Here, we developed and evaluated pVAX1-TgIMC1-loaded PLGA and chitosan (CS) nanospheres as potential vaccine candidates. Immunization studies in mice showed that pVAX1-TgIMC1/PLGA and pVAX1-TgIMC1/CS nanospheres induced robust humoral and cellular immune responses, significantly enhancing specific IgG levels and cytokine production IFN-γ and IL-17 compared to the naked DNA vaccine. Both nanospheres also promoted dendritic cell maturation and T-cell activation, resulting in reduced parasite burdens in cardiac tissues post-challenge. Notably, the PLGA nanospheres exhibited superior protection against acute toxoplasmosis, while CS nanospheres provided additional advantages in antigen stability and delivery. The nanospheres were non-toxic, as confirmed by biochemical markers and histopathological analysis. These findings highlight pVAX1-TgIMC1/PLGA and pVAX1-TgIMC1/CS nanospheres as promising candidates for T. gondii vaccine development, warranting further optimization and validation in broader animal models."],"journal":["BMC veterinary research"],"pubmed_title":["Research on inner membrane complex protein 1: a novel nanovaccines against Toxoplasma gondii."],"pmcid":["PMC12374472"],"funding_grant_id":["2024BEH04076","NSFC, 72203117","2023RC-2-5","NKYG-25-22"],"pubmed_authors":["Fang Y","Jiang Y","Zhou P","Qi W","Wang X","Zhang L","Yu Z","Liu T","Wang J","Yu Y"],"additional_accession":[]},"is_claimable":false,"name":"Research on inner membrane complex protein 1: a novel nanovaccines against Toxoplasma gondii.","description":"Toxoplasma gondii (T. gondii) is a globally prevalent zoonotic parasite causing severe health and economic impacts. Despite decades of research, no commercial vaccine provides comprehensive protection against both acute and chronic toxoplasmosis. DNA vaccines represent a promising strategy, but their application is hindered by low delivery efficiency and limited immunogenicity. Here, we developed and evaluated pVAX1-TgIMC1-loaded PLGA and chitosan (CS) nanospheres as potential vaccine candidates. Immunization studies in mice showed that pVAX1-TgIMC1/PLGA and pVAX1-TgIMC1/CS nanospheres induced robust humoral and cellular immune responses, significantly enhancing specific IgG levels and cytokine production IFN-γ and IL-17 compared to the naked DNA vaccine. Both nanospheres also promoted dendritic cell maturation and T-cell activation, resulting in reduced parasite burdens in cardiac tissues post-challenge. Notably, the PLGA nanospheres exhibited superior protection against acute toxoplasmosis, while CS nanospheres provided additional advantages in antigen stability and delivery. The nanospheres were non-toxic, as confirmed by biochemical markers and histopathological analysis. These findings highlight pVAX1-TgIMC1/PLGA and pVAX1-TgIMC1/CS nanospheres as promising candidates for T. gondii vaccine development, warranting further optimization and validation in broader animal models.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-05-08T10:46:21.67Z","creation":"2026-04-07T23:47:23.681Z"},"accession":"S-EPMC12374472","cross_references":{"pubmed":["40849645"],"doi":["10.1186/s12917-025-04961-z"]}}